Paper39264187
An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds.
Duffy S and 2 others. Antimicrob Agents Chemother, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds. Papers, record 39264187. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39264187
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimalarials | Major topic |
| High-Throughput Screening Assays | Major topic |
| Plasmodium falciparum | |
| Humans | |
| Drug Discovery | |
| Malaria | |
| Animals | |
| Parasitic Sensitivity Tests |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| AP1150359 | DHAC | National Health and Medical Research Council (NHMRC) | PubMed |
Source PubMed
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 394674 | Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. | Antimicrob Agents Chemother | 1979 | https://conductscience.org/library/papers/394674 | PubMed |
| 2 | 38486232 | A phenotypic screen of the Global Health Priority Box identifies an insecticide with anthelmintic activity. | Parasit Vectors | 2024 | https://conductscience.org/library/papers/38486232 | PubMed |
| 3 | 18579134 | Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter. | Exp Parasitol | 2008 | https://conductscience.org/library/papers/18579134 | PubMed |
| 4 | 25007124 | N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds. | J Med Chem | 2014 | https://conductscience.org/library/papers/25007124 | PubMed |
| 5 | 35647647 | High-Throughput Screening Platform To Identify Inhibitors of Protein Synthesis with Potential for the Treatment of Malaria. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35647647 | PubMed |
| 6 | 24731288 | Repositioning: the fast track to new anti-malarial medicines? | Malar J | 2014 | https://conductscience.org/library/papers/24731288 | PubMed |
| 7 | 22877082 | Review of pyronaridine anti-malarial properties and product characteristics. | Malar J | 2012 | https://conductscience.org/library/papers/22877082 | PubMed |
| 8 | 35229610 | Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria. | J Med Chem | 2022 | https://conductscience.org/library/papers/35229610 | PubMed |
| 9 | 37471441 | A screen of drug-like molecules identifies chemically diverse electron transport chain inhibitors in apicomplexan parasites. | PLoS Pathog | 2023 | https://conductscience.org/library/papers/37471441 | PubMed |
| 10 | 22390538 | 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. | J Med Chem | 2012 | https://conductscience.org/library/papers/22390538 | PubMed |
| 11 | 29311064 | High-Content Screening of the Medicines for Malaria Venture Pathogen Box for Plasmodium falciparum Digestive Vacuole-Disrupting Molecules Reveals Valuable Starting Points for Drug Discovery. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29311064 | PubMed |
| 12 | 31665424 | The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/31665424 | PubMed |
| 13 | 25453091 | (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/25453091 | PubMed |
| 14 | 29355852 | Drug resistance in Plasmodium. | Nat Rev Microbiol | 2018 | https://conductscience.org/library/papers/29355852 | PubMed |
| 15 | 29892073 | Diverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasis. | Sci Rep | 2018 | https://conductscience.org/library/papers/29892073 | PubMed |
| 16 | 28446690 | Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. | Sci Transl Med | 2017 | https://conductscience.org/library/papers/28446690 | PubMed |
| 17 | 34452759 | Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity. | Bioorg Chem | 2021 | https://conductscience.org/library/papers/34452759 | PubMed |
| 18 | 22383983 | P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. | PLoS One | 2012 | https://conductscience.org/library/papers/22383983 | PubMed |
| 19 | 33929818 | Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors. | ACS Infect Dis | 2021 | https://conductscience.org/library/papers/33929818 | PubMed |
| 20 | 37435490 | Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37435490 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42662730 | Drug Repositioning for Multiresistant Staphylococcus aureus and Escherichia coli from Pandemic Response Box and Global Health Priority Box of MMV. | ACS Omega | 2026 | https://conductscience.org/library/papers/42662730 | PubMed |
| 42085784 | Unpacking boxes: identification of novel inhibitors of malaria parasite invasion. | Int J Parasitol Drugs Drug Resist | 2026 | https://conductscience.org/library/papers/42085784 | PubMed |
| 41970896 | Indole Peptidomimetics Show Potent and Selective Activity against Drug-Resistant Plasmodium falciparum. | ACS Omega | 2026 | https://conductscience.org/library/papers/41970896 | PubMed |
| 41009722 | Targeting Mitochondrial Function in Plasmodium falciparum: Insight into Antimalarial Drugs and the Emerging Role of Saccharomyces cerevisiae as a Model System. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41009722 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39264187
GET https://conductscience.org/api/papers/v1/39264187/references?page=2